- Home
- PRSU vs GYRE Comparison
PRSU vs GYRE Comparison
Compare PRSU & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRSU
- GYRE
- Stock Information
- Founded
- PRSU 1926
- GYRE 2002
- Country
- PRSU United States
- GYRE United States
- Employees
- PRSU N/A
- GYRE N/A
- Industry
- PRSU Business Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- PRSU Consumer Discretionary
- GYRE Health Care
- Exchange
- PRSU Nasdaq
- GYRE Nasdaq
- Market Cap
- PRSU 876.5M
- GYRE 997.3M
- IPO Year
- PRSU N/A
- GYRE N/A
- Fundamental
- Price
- PRSU $37.65
- GYRE $11.54
- Analyst Decision
- PRSU Buy
- GYRE
- Analyst Count
- PRSU 1
- GYRE 0
- Target Price
- PRSU $50.00
- GYRE N/A
- AVG Volume (30 Days)
- PRSU 263.0K
- GYRE 52.5K
- Earning Date
- PRSU 03-04-2025
- GYRE 03-25-2025
- Dividend Yield
- PRSU N/A
- GYRE N/A
- EPS Growth
- PRSU 58.18
- GYRE N/A
- EPS
- PRSU 1.06
- GYRE N/A
- Revenue
- PRSU $1,399,418,000.00
- GYRE $105,033,000.00
- Revenue This Year
- PRSU $3.17
- GYRE $25.32
- Revenue Next Year
- PRSU N/A
- GYRE $12.95
- P/E Ratio
- PRSU $38.25
- GYRE N/A
- Revenue Growth
- PRSU 17.10
- GYRE N/A
- 52 Week Low
- PRSU $29.46
- GYRE $8.26
- 52 Week High
- PRSU $47.49
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- PRSU N/A
- GYRE 47.99
- Support Level
- PRSU N/A
- GYRE $12.09
- Resistance Level
- PRSU N/A
- GYRE $12.80
- Average True Range (ATR)
- PRSU 0.00
- GYRE 0.56
- MACD
- PRSU 0.00
- GYRE -0.00
- Stochastic Oscillator
- PRSU 0.00
- GYRE 16.39
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.